Quantification of Nitric oxide in Multiple Myeloma Algerian Patients Using R&D and Arbor Assays Kits

Abstract

Nitric oxide (NO) is an instable free radical considered as a marker of physiological and pathological processes. NO quantification is very sensitive and shows a great variability because of the NO short life time. Myeloma bone diseases (MBD) constitute one of the most visible aspects in MM cancer, which is a favorable microenvironment for the promotion of communication between malignant plasma cells and other cell types using cellular messengers including NO. On the other hand, many researchers have confirmed the association of osteoporosis with a high concentration of (NO), which has been proven to play a primary role in bone remodeling. The relationship between plasma NO concentration and MM pathology is poorly documented. This work aimed to study the variability of NO quantification using R&D and Arbor assays kits in plasma MM patients in comparison with osteoporosis (OP) patients as positive control. MM and OP blood samples were obtained from patients in three hospitals at the East of Algeria. The results showed a slight similarity (21.56%) between NOx concentrations assayed with two kits, that the average concentration of NOx in MM patients(54, 22μM / l ±20, 06μM/l) was higher than the average concentration of NOx in patients with OP (48,34μM/l ±16,71μM /l). Our results confirmed an important difference and variability in NO quantification Thus the high NOx level production in MM patients comparing with OPpatients was noticed.